People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc. | — | Biotechnology | Series D+ | $200.0M | $2.5B | 2024 |
Melissa McCracken, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Melissa McCracken, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Robert More | 1 | 7 |
| Alan Fuhrman | 1 | 5 |
| Gilla Kaplan, Ph.D. | 1 | 2 |
| Jake Simson, Ph.D. | 1 | 2 |
| Sid Subramony, Ph.D. | 1 | 1 |
| Todd Harris, Ph.D. | 1 | 1 |
| Hiroomi Tada, M.D., Ph.D. | 1 | 1 |
| Isan Chen, M.D. | 1 | 1 |
| Daniel Bensen | 1 | 1 |
| Rehan Verjee | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.